286 related articles for article (PubMed ID: 26581390)
21. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Golfmann K; Meder L; Koker M; Volz C; Borchmann S; Tharun L; Dietlein F; Malchers F; Florin A; Büttner R; Rosen N; Rodrik-Outmezguine V; Hallek M; Ullrich RT
Oncogene; 2018 Oct; 37(42):5682-5693. PubMed ID: 29970903
[TBL] [Abstract][Full Text] [Related]
22. Tenascin-C increases lung metastasis by impacting blood vessel invasions.
Sun Z; Velázquez-Quesada I; Murdamoothoo D; Ahowesso C; Yilmaz A; Spenlé C; Averous G; Erne W; Oberndorfer F; Oszwald A; Kain R; Bourdon C; Mangin P; Deligne C; Midwood K; Abou-Faycal C; Lefebvre O; Klein A; van der Heyden M; Chenard MP; Christofori G; Mathelin C; Loustau T; Hussenet T; Orend G
Matrix Biol; 2019 Oct; 83():26-47. PubMed ID: 31288084
[TBL] [Abstract][Full Text] [Related]
23. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
24. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
25. Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.
Farrugia MK; Sharma SB; Lin CC; McLaughlin SL; Vanderbilt DB; Ammer AG; Salkeni MA; Stoilov P; Agazie YM; Creighton CJ; Ruppert JM
Cell Death Dis; 2015 Mar; 6(3):e1699. PubMed ID: 25789974
[TBL] [Abstract][Full Text] [Related]
26. Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrence.
Jones RA; Moorehead RA
Genes Chromosomes Cancer; 2019 Jun; 58(6):381-391. PubMed ID: 30597648
[TBL] [Abstract][Full Text] [Related]
27. Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
Kacan T; Altun A; Altun GG; Kacan SB; Sarac B; Seker MM; Bahceci A; Babacan N
Asian Pac J Cancer Prev; 2014; 15(7):3185-9. PubMed ID: 24815468
[TBL] [Abstract][Full Text] [Related]
28. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
[TBL] [Abstract][Full Text] [Related]
29. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
30. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
[TBL] [Abstract][Full Text] [Related]
31. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
32. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
Xiao L; Du E; Homer-Bouthiette C; Hurley MM
Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
[TBL] [Abstract][Full Text] [Related]
33. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
[TBL] [Abstract][Full Text] [Related]
34. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
35. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
37. Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment.
García-Mendoza MG; Inman DR; Ponik SM; Jeffery JJ; Sheerar DS; Van Doorn RR; Keely PJ
Breast Cancer Res; 2016 May; 18(1):49. PubMed ID: 27169366
[TBL] [Abstract][Full Text] [Related]
38. A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis.
Wang W; Meng Y; Dong B; Dong J; Ittmann MM; Creighton CJ; Lu Y; Zhang H; Shen T; Wang J; Rowley DR; Li Y; Chen F; Moore DD; Yang F
Neoplasia; 2017 May; 19(5):421-428. PubMed ID: 28433771
[TBL] [Abstract][Full Text] [Related]
39. Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Tilio M; Gambini V; Wang J; Garulli C; Kalogris C; Andreani C; Bartolacci C; Elexpuru Zabaleta M; Pietrella L; Hysi A; Iezzi M; Belletti B; Orlando F; Provinciali M; Galeazzi R; Marchini C; Amici A
Cancer Lett; 2016 Oct; 381(1):76-84. PubMed ID: 27475932
[TBL] [Abstract][Full Text] [Related]
40. Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.
Schmidt K; Moser C; Hellerbrand C; Zieker D; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
Anticancer Res; 2015 Dec; 35(12):6655-65. PubMed ID: 26637881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
